Thomas Hennessey

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022.

Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022.

Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

AutoGenomics, Inc. engages in the design, development, manufacture, and marketing of an automated, microarray-based multiplexing diagnostic platform. The company was founded by Fareed Kureshy, Shailendra Singh, and Ramanath Vairavan in April 1999 and is headquartered in Carlsbad, CA.

Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022.